![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Curis Doses First Patient in Phase I Trial for Basal Cell Carcinoma
Curis Doses First Patient in Phase I Trial for Basal Cell Carcinoma
June 8, 2005
Curis has announced that the first patient in the basal cell carcinoma (BCC) Phase I trial has been dosed.
This Phase I clinical trial is being conducted by Genentech and Curis. This drug candidate, a topical antagonist of the Hedgehog signaling pathway, was discovered by Curis and is being co-developed through a collaboration between Genentech and Curis.
The Phase I study is a double-blind, randomized, placebo-controlled study that will enroll approximately 66 subjects with a single or multiple basal cell carcinoma. The study will be conducted at approximately 10 investigational sites in the U.S. The primary outcomes measured in this trial will be the safety and tolerability of a multidose regimen of the Hedgehog antagonist.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct